TGFB2 (Transforming Growth Factor Beta 2)

Our results establish SMAD4 SUMOylation as a pivotal molecular switch in lens fibrosis pathogenesis. Employing inhibitory drugs of SUMO conjugation in the years to come has the potential to be a novel therapeutic strategy for fibrotic cataracts.

To encapsulate our findings, we have determined eight MAPK pathway-associated CRC prognostic biomarkers and developed a prognostic model accordingly. This model has proven effective in stratifying the risk levels among CRC patients.

although individual treatments provided benefits, their combined use enhanced therapeutic outcomes through modulation of oxidative stress, inflammation, and androgenic activity in BPH management.

Although TGFβ ligands can potently induce growth arrest in cells of epithelial origin, we show that TGFβ1 and TGFβ2 promote cell invasion of EwS cells without affecting proliferation. Thus, stroma-derived and tumor-derived TGFβ ligands induce and maintain hybrid EwS cells to promote pro-metastatic cell phenotypes.

MRPL58 represents a promising therapeutic target. Disrupting exosome-mediated immunosuppression could enhance DC-based vaccines and combination immunotherapies for leukemia.

It allows real-time assessment of EMT progression and is suitable for screening anti-fibrotic compounds. Our findings suggest that Nicotinamide mitigates both fibrotic and angiogenic responses in this model and may hold therapeutic potential for fibrotic retinal diseases.

This study provides insights into the molecular mechanisms underlying PAAD and establishes a theoretical foundation for the development of CAF-targeting therapeutic strategies.

THBS1 and ENG are significant prognostic biomarkers and potential therapeutic targets in GBM. Their strong correlation with immunosuppressive M2 macrophage infiltration implicates actin cytoskeleton remodeling pathways in GBM-mediated immune evasion. Targeting these hub genes may disrupt critical tumor microenvironment interactions, offering new avenues for therapy.

Tolvaptan is the only FDA-approved drug to treat ADPKD, which has significant side effects, prompting the need for safer novel treatments...4l's efficiency across 2D, 3D, and iPSC-derived models highlights its therapeutic potential. This study also recognizes mitophagy and necroptosis as novel targets in ADPKD and corroborates iPSC-derived renal cells as a powerful platform for drug screening.

This study proposes a panel of potential prognostic biomarkers for the treatment of ovarian cancer patients, particularly by leveraging TGFB2-dependent mRNA expression as a significant biomarker, alongside four additional TGFB2-independent prognostic markers, for patients undergoing Taxol-based therapies. Future prospective clinical trials will be required to validate these prognostic markers.

Under hypoxic conditions, miR-652-5p promoter hypermethylation promotes GBM malignancy via the SDC1/TGFβ2/pERBB4 axis in a HIF2α-dependent manner. Understanding this mechanism may lead to the development of epigenetic treatments and personalized medical approaches to improve patient outcomes.

Protein-protein interaction (STRING) analysis indicated that TGFB2 is associated with EGFR and MYC from the PAM50 breast cancer gene signature. These findings suggest that correlation of TGFB2-related markers could potentially complement the PAM50 signature in the assessment of OS prognosis in breast cancer patients, but further validation of the TGFB2/EGFR/MYC proteins in tumors is warranted.